

Evaluation of Broncho-Vaxom(R) ability to respond to the induction of inflammation through the inhalation of a bacterial component

Submission date 18/09/2012	Recruitment status No longer recruiting	☐ Prospectively registered ☐ Protocol
Registration date 24/10/2012	Overall study status Completed	☐ Statistical analysis plan ☐ Results
Last Edited 24/10/2012	Condition category Respiratory	☐ Individual participant data ☐ Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Stefan Zielen

Contact details
Zentrum für Kinder- und Jugendmedizin
Allergologie, Pneumologie und Mukoviszidose
Klinikum der Johann Wolfgang Goethe-Universität
Theodor-Stern-Kai 7
Frankfurt/Main
Germany
60590

Additional identifiers

Protocol serial number
BV2012/05

Study information

Scientific Title

Clinical and immune modifying capacity of Broncho-Vaxom tested by LPS challenge in healthy volunteers

Study objectives

To demonstrate that healthy volunteers treated with Broncho-Vaxom (BV) will develop total antibody levels (i.e. total secretory IgA in saliva) after 4 weeks of treatment compared to placebo.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics Committee of the State Medical Association Hesse, 27 August 2012, ref: FF61/2012

Primary study design

Interventional

Study design

Randomized double-blind placebo-controlled single center phase II trial

Study type(s)

Screening

Health condition(s) or problem(s) studied

Bronchitis

Interventions

Skin prick test, blood sampling, at visit 4, all subjects will inhale a single dose of 50ug Escherichia coli - Lipopolysaccharide via a medic aid nebulizer and an aerosol provocation system powered by compressed air, ECG and spirometry

Intervention Type

Other

Phase

Phase II

Primary outcome(s)

The change from baseline on total IgA level in saliva after 4 weeks of treatment

Key secondary outcome(s)

1. The reduction of the inflammatory response after a LPS inhalation challenge
2. The reduction on one of the following LPS-induced responses:
 - 2.1. Leukocytes, neutrophils, CRP, LPS-binding protein (LBP) levels in serum
 - 2.2. Neutrophilic inflammation and inflammatory cytokines in induced sputum
 - 2.3. Bronchoconstriction (FEV1 decrease)
 - 2.4. Local symptoms: cough, chest tightness
 - 2.5. Systemic effects like increase of body temperature, chills and headache

Completion date

Eligibility

Key inclusion criteria

1. Patients who have been informed of the study procedures and medications and have given their written informed consent
2. Healthy male and female of any race
3. Aged 18 to 45 years

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 Years

Sex

All

Key exclusion criteria

1. Have received systemic or inhaled corticosteroids within 4 weeks before Visit 1
2. Have smoked on a regular basis within 2 years before Visit 1 or who have a smoking history > 10 pack years
3. An active lung disease (e.g. asthma, chronic bronchitis, COPD)
4. Have suffered from a respiratory tract infection within 4 weeks preceding the study period.
5. Predicted FEV1 below 80% at visit 1
6. Clinically significant uncontrolled systemic disease or a history of such disease (e.g. cancer, infection, hematological disease, renal, hepatic, coronary heart disease or other cardiovascular disease, endocrinology or gastrointestinal disease) within the previous 3 months
7. Clinically significant laboratory abnormalities at Visit 1
8. A platelet count less or equal to $130 \times 10^9/L$ at Visit 1
9. A result for Methacholine-test below 0.1 mg at Visit 1
10. Skin prick test result >5mm and a corresponding history of allergic asthma
11. With a clinically significant abnormal finding detected on Electrocardiogram at visit 1
12. A history of food or drug related severe anaphylactoid or anaphylactic reaction(s)
13. Are pregnant or nursing mothers
14. Who are of child bearing potential and who are not protected by a reliable contraceptive method (oral, subcutaneous, mechanical, or surgical contraception). Any woman who becomes pregnant during the course of the study must be discontinued, any female who starts her menarche during the trial and is not, for whatever reason, protected by a medically approved contraception must be withdrawn from the trial
15. Known hypersensitivity to any ingredients of BV
16. Volunteers who are considered potentially unreliable and volunteers who may not reliably attend study drug visits
17. A history of drug or alcohol abuse

18. Are unable to perform spirometry and peak flow measurements or complete the subject's diary

19. Have participated in another clinical study within 3 months prior to Visit 1

Date of first enrolment

29/08/2012

Date of final enrolment

31/01/2013

Locations

Countries of recruitment

Germany

Study participating centre

Zentrum für Kinder- und Jugendmedizin

Frankfurt/Main

Germany

60590

Sponsor information

Organisation

OM Pharma [Vifor Pharma] (Switzerland)

ROR

<https://ror.org/0185z7g17>

Funder(s)

Funder type

Industry

Funder Name

OM Pharma [Vifor Pharma] (Switzerland)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration